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Abstract: 
The hereditary spastic paraplegias (HSPs) are a heterogeneous group of disorders 
characterized by degeneration of the corticospinal and spinocerebellar tracts leading to 
progressive spasticity. One subtype, spastic paraplegia type 47 (SPG47 or HSP-
AP4B1), is due to bi-allelic loss-of-function mutations in the AP4B1 gene. AP4B1 is a 
subunit of the adapter protein complex 4 (AP-4), a heterotetrameric protein complex that 
regulates the transport of membrane proteins. Since 2011, eleven individuals from six 
families with AP4B1 mutations have been reported, nine of whom had homozygous 
mutations and were from consanguineous families. Here we report eight patients with 
AP4B1-associated SPG47, the majority born to non-consanguineous parents and 
carrying compound heterozygous mutations. Core clinical features in this cohort and 
previously published patients include neonatal hypotonia that progresses to spasticity, 
early-onset developmental delay with prominent motor delay and severely impaired or 
absent speech development, episodes of stereotypic laughter, seizures including 
frequent febrile seizures, thinning of the corpus callosum, and delayed myelination/white 
matter loss.  Given that some of the features of AP-4 deficiency overlap with those of 
cerebral palsy, and the discovery of the disorder in non-consanguineous populations, 
we believe that AP-4 deficiency may be more common than previously appreciated. 
 
Key Words: hereditary spastic paraplegia, SPG47, AP4B1, microcephaly, intellectual 
disability, seizures, thin corpus callosum, cerebral palsy 
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INTRODUCTION 
The hereditary spastic paraplegias (HSP) are a heterogeneous group of diseases 
characterized by a progressive degeneration of the spinothalamic tracts leading to 
spastic para- or tetraplegia. Bi-allelic loss of function mutations in any of the four 
adapter protein 4 (AP-4) complex subunits lead to spastic paraplegia and intellectual 
disability. AP-4 belongs to a family of adaptor proteins (AP-1 through AP-5), which are 
evolutionarily conserved heterotetrameric protein complexes that mediate vesicle 
trafficking in cells (Hirst et al., 2013). The AP-4 complex is composed of four subunits 
(β4, ε, µ4, σ4) and is involved in trafficking of membrane proteins from the trans-Golgi-
network. Mutations in the genes for each subunit have been reported to cause complex 
forms of HSP (Marras et al., 2016): AP4B1 (HSP-AP4B1 or SPG47, OMIM #614066), 
AP4E1 (HSP-AP4E1 or SPG51, OMIM #613744), AP4M1 (HSP-AP4M1 or SPG50, 
OMIM #612936), and AP4S1 (HSP-AP4S1 or SPG52, OMIM #614067). Mutations in 
AP4B1 have been thus far reported in eleven individuals from six pedigrees, mostly 
consanguineous families with homozygous mutations (Abdollahpour et al., 2015; Abou 
Jamra et al., 2011; Bauer et al., 2012; Lamichhane, 2013; Tan et al., 2015; Tuysuz et 
al., 2014). Here we report a detailed clinical, imaging, and molecular characterization of 
eight individuals with bi-allelic mutations in AP4B1. Five of these individuals had 
compound heterozygous mutations, and several recurrent mutations were identified. 
This is the largest cohort of patients with AP4B1 mutations reported to date, and 
demonstrates the presence of this disorder in populations with low rates of 
consanguinity. 
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METHODS AND MATERIALS 
Patients were recruited into the collaborating institutions’ review board and/or ethics 
committee–approved research protocols, and written informed consent for participation, 
including publishing photographs and videos, was obtained. Social media and the 
CureSPG47 website (www.curespg47.org) were used by some families to connect with 
other families and the investigators. Data were collected through a retrospective, cross-
sectional review of medical records. Brain imaging was performed on all patients, and 
ten MRI brain scans were available for review. Genetic testing was done using multi-
gene panels or exome sequencing. Variants were annotated using the ExAC database 
and interrogated in silico to predict damaging effects (by calculating Combined 
Annotation Dependent Depletion (CADD) scores (Kircher et al., 2014)). Phenotypes of 
previously published individuals with AP4B1 mutations were also reviewed.  
 
RESULTS 
Clinical Characterization  
We identified eight individuals with bi-allelic AP4B1 mutations from seven unrelated 
families. The phenotypes of the cohort are summarized in Table 1. In our cohort, the 
majority of patients were female (7/8). All were born at term without significant perinatal 
complications. The neonatal course was complicated by hypoglycemia and periodic 
breathing in two patients (P2 and P3). The age at initial presentation for concerns of 
developmental delay was early, generally between 2 – 4 months of age, with an 
average age at diagnosis of 54 months (range: 26 months – 12 years). Excluding two 
siblings, who presented for genetic evaluation at significantly older ages and were 
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identified at ages 6 and 12 years, respectively, reduces the average age at diagnosis to 
36 months. 
All eight patients presented with early developmental delay with prominently 
delayed motor milestones. Rolling was delayed to 5 – 7 months, independent sitting to 8 
– 11 months, crawling to 11 – 30 months and walking, if achieved and generally with 
assistance, to 27-35 months. Truncal and appendicular hypotonia was universally noted 
in early infancy and progressed to lower extremity spasticity, leading to spastic 
paraplegia and impaired ambulation. Several individuals were thought to have cerebral 
palsy prior to genetic diagnosis. The oldest individual in our cohort progressed to 
spastic tetraplegia with more prominent involvement of the lower extremities (Table 1). 
Generalized dystonic movements were described in one patient (P7). In patients who 
continued to walk with assistance, a wide-based, unsteady spastic gait was described. 
Speech development was delayed in all children and remained limited to a few words 
with two individuals remaining non-verbal. Microcephaly (head circumference 
decreased by ≥2 SD) was reported in five patients, but the range was mild (-2 to -3SD), 
with three patients being normocephalic. Height and weight were normal in the majority 
of patients. Facial features seen in more than one individual include prominent cheeks, 
a thin upper vermilion and a flat nasal bridge, but these features do not appear unique 
enough to make this a recognizable syndrome (Figure 1). Unprovoked seizures 
qualifying for a diagnosis of epilepsy occurred in four children with onset within the first 
two years of life. Febrile seizures were also common and occurred in three additional 
patients. Of note, the “shy character” previously described in two families (Abdollahpour 
et al., 2015; Abou Jamra et al., 2011) was not present. All eight children in our cohort 
 7 
were described as social and with a generally happy demeanor. Characteristic and 
stereotypic episodes of laughter were independently reported in at least five individuals 
(Video 1). All patients received supportive care including early intervention, physical, 
occupational and speech therapy.  
In addition to reporting phenotypes of eight new patients, we reviewed the 
literature for previous reports of individuals with AP4B1 mutations, which are included in 
Table 1. Including the patients identified in this paper, a total of 19 individuals with 
AP4B1 mutations have now been identified, and a core set of clinical features has 
emerged (Table 2). Manifestations shared by the majority of individuals include: early 
developmental delay and intellectual disability (19/19, 100%) with prominent motor 
(17/17, 100%) and speech (16/17, 94%) delays, neonatal or infantile hypotonia (15/15, 
100%) progressing to spastic diplegia (17/19, 89%) with loss or failure to achieve 
independent walking (15/17, 88%). Mild microcephaly (-2 to -3SD range) and short 
stature are found in 69% and 57% of individuals respectively. Peculiar episodes of 
stereotypic laughter, first video-documented here (Video 1), were found in about two 
thirds of patients. Epilepsy, defined as more than two unprovoked seizures, occurred in 
about half the patients. Febrile seizures were also common, occurring in an additional 
six patients. 
Spastic paraplegia has not yet developed in two young patients (P2 and P3, 
aged 32 and 31 months respectively), although an abnormal, unsteady gait was noted. 
Progression to tetraplegia was documented in the two oldest patients in our cohort (P6 
and P8) and at least four previously reported patients who became non-ambulatory after 
the age of 10 years. 
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Brain Imaging 
Brain imaging is summarized in Table 1 and illustrated in Figure 2. Serial studies were 
available in three patients (P1, P4 and P5). Delayed myelination and/or white matter 
loss in the periventricular and other supratentorial regions was present in all patients but 
one (P4). A thin corpus callosum particularly affecting the posterior aspects was noted 
in 6/7 patients. Ventriculomegaly was seen in three patients, mostly in the form of 
prominent colpocephaly, and in one patient even detected prenatally (P5). Comparison 
with imaging findings of previously reported patients (Table 1), confirmed the high 
prevalence of these findings (Table 2). 
 
Molecular Characterization 
We identified a total of nine AP4B1 mutations in eight patients from seven families 
(Table 3, Figure 3, Supplementary Table 1). Two of these mutations (p.L222Cfs*31 and 
p.T387Rfs*30) have been previously reported (Abdollahpour et al., 2015; Abou Jamra et 
al., 2011; Bauer et al., 2012; Lamichhane, 2013; Tan et al., 2015; Tuysuz et al., 2014). 
In most patients (7/8), AP4B1 mutations were identified by exome sequencing. Four 
patients were of European descent, two patients were of mixed ethnicity and two 
patients (siblings) were of South Asian (Tamil) origin. Consanguinity was reported in two 
families and shared ancestry in one (Table 1). Four patients (P1 – P4) had no history of 
shared ancestry and had compound heterozygous mutations (Table 1 and 3). 
Interestingly, two unrelated individuals (P1 and P4) in our cohort shared the same 
compound heterozygous mutation (p.Arg406* / p.Leu443Pro). 
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The literature includes two reports of patients with AP4B1 mutations in which little 
clinical information was provided (Helbig et al., 2016; Karaca et al., 2015). We included 
this data in our mutation summaries (Table 3, Figure 3, Supplementary Table 1), but did 
not in our summary of clinical characteristics (Table 1).  
Including mutations identified in this report as well as the literature, there are now 
a total of 17 unique mutations in AP4B1, 5 of which are recurrent (Table 3). The majority 
(11/17) are frameshifting or nonsense mutations. Two splice site mutations are at the 
same splice acceptor site, and 4 missense mutations have been described. The most 
common mutation in AP4B1 is c.664delC. One mutation (p.Thr387Argfs*30) is seen in 
both homozygous (P1 in (Abdollahpour et al., 2015)) and compound heterozygous state 
(P3). 
 
DISCUSSION 
We report a series of eight new patients with bi-allelic AP4B1 mutations from 
mostly non-consanguineous families, and combine detailed clinical, imaging, and 
molecular characterization of these patients with the 11 patients previously reported. 
Together, these 19 patients begin to define a core set of features (Table 2).  
These consist of a combination of early developmental delay and intellectual 
disability, prominently delayed motor and speech development, infantile-onset 
hypotonia that progresses to symmetric spastic diplegia with loss of independent 
ambulation, mild (-2 to -3SD) microcephaly and episodes of stereotypic laughter. 
Epilepsy is a variable manifestation and is seen in about half of all patients. Although 
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some of the individuals have overlapping facial features, a “recognizable” dysmorphic 
facial phenotype is not readily apparent (Figure 1). 
Characteristic brain imaging findings include a triad of thin corpus callosum, 
delayed myelination or loss of supratentorial white matter, and associated 
ventriculomegaly (Figure 2). 
Mutations in AP4B1 were detected by exome sequencing or multi-gene panels 
(Table 3). An additional four individuals were identified in large cohorts referred for 
exome sequencing for epilepsy (Helbig et al., 2016) or developmental brain 
malformations (Karaca et al., 2015) without detailed clinical data available. The majority 
(11/17) of mutations are frameshifting or nonsense mutations that likely lead to 
nonsense-mediated RNA degradation (Hirst et al., 2013). This strongly suggests the 
molecular mechanism behind this autosomal-recessive disease is loss of function. The 
c.664delC (p.Leu222Cysfs*31) mutation was found in five patients from three families, 
making this the most common mutation in AP4B1. This mutation has thus far only been 
seen in homozygous individuals with Arab/Turkish ancestry, so it may be specific to this 
population. It could also represent a mutational hotspot as this cytosine base is located 
within a short tract of thymine bases.  
Two unrelated patients in our cohort shared identical mutations: c.1216C>T 
(p.Arg406*) / c.1328T>C (p.Leu443Pro). The ExAC minor allele frequency of 
c.1216C>T is 0.01153% (14 out of 121372 alleles) and c.1328T>C is 0.00083% (1 out 
of 121244 alleles) both of these variants are rare. We cannot explain this observation at 
the present, but speculate that only a limited number of missense mutations will be 
deleterious enough to AP-4 function to produce disease. Experiments reproducing this 
 11 
and other AP4B1 missense mutations in model systems are needed to address this 
question. 
Several individuals in our cohort were diagnosed by exome sequencing within 3 
– 4 months of each other. This suggests that this disorder is likely under-diagnosed at 
the present, and the increasing use of exome sequencing will undoubtedly lead to the 
identification of more individuals with this disorder. Due to overlapping clinical features, 
patients with AP4B1 related SPG47 may be misdiagnosed as having cerebral palsy. 
Indeed several individuals in our cohort were thought to have cerebral palsy prior to 
genetic diagnosis. Clues that can help distinguish AP4B1-related spastic paraplegia 
from cerebral palsy include the brain MR findings, the progressive nature of the disease 
and the severity of the speech delay. The early onset of developmental delay and 
microcephaly, when present, are also somewhat atypical for cerebral palsy. Due to the 
25% recurrence risk for this autosomal-recessive disorder, it is a critically important 
diagnosis to make. 
Seven out of the eight newly identified patients are female, and in the total cohort 
of 19 patients, only six are males. This cause of this sex imbalance is currently 
unknown. A skewed sex ratio in cerebral palsy has been previously noted, but in the 
opposite direction from what we observe. Cerebral palsy has been noted to occur 1.3 to 
1.4 times more often in males than in females (Romeo et al., 2016). It is possible that 
males with biallelic AP4B1 mutations are more severely affected and do not survive 
long enough to be tested, although no difference in phenotypic severity is noted in the 
six males with AP4B1-related SPG47. It is also possible that males with the disease are 
less likely to receive testing because they are thought to have cerebral palsy. 
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Several of the families in our cohort identified each other using social media. In 
the current era of exome sequencing, social media has become an increasingly 
common and effective tool for families with rare disorders. The efforts of the families in 
this study, represented by the CureSPG47 foundation (www.CureSPG47.org) have 
significantly enabled this collaborative research effort. 
There are striking similarities between the phenotypes that arise from mutations 
in AP4B1 and the other three subunits of AP-4. Patients with AP4E1 (Moreno-De-Luca 
et al., 2011), AP4M1 (Jameel et al., 2014; Tuysuz et al., 2014; Verkerk et al., 2009) and 
AP4S1 (Hardies et al., 2015; Tessa et al., 2016) mutations also present with spastic 
para- or tetraplegia, intellectual disability, delayed or absent speech development, 
microcephaly, seizures and febrile seizures in particular, and many have pseudobulbar 
signs such as stereotypic laughter, indicating a common phenotype that arises from loss 
of AP-4. Thus enhanced understanding of AP4B1-SPG47 will likely benefit the other 
AP-4 related disorders. 
The AP-4 complex has been shown to be involved in protein trafficking from the 
trans-Golgi network to early and late endosomes but also the plasma membrane 
(Bonifacino, 2014; Hirst et al., 2013). In neuronal models, AP-4 was found to mediate 
AMPA receptor trafficking with Ap4b1-/- mice showing mislocalization of AMPA 
receptors to distal axons, where they were found within autophagosomes (Matsuda et 
al., 2008). The link to neuronal autophagy is compelling given the clinical overlap 
between AP4B1-SPG47 and the congenital disorders of autophagy (Ebrahimi-Fakhari et 
al., 2016), in which the long white matter tracts are often prominently affected. Further 
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research is needed to understand the molecular mechanisms by which loss of AP-4 
function leads to degeneration of the long white matter tracts and other manifestations.  
In summary, AP4B1-associated HSP and other AP-4-deficiency syndromes 
should be suspected in infants and children with hypotonia progressing to spastic 
paraplegia, delayed motor and speech development, and suggestive findings on brain 
imaging particularly thinning of the posterior aspect of the corpus callosum. Given the 
rarity of many forms of HSP, patients with childhood-onset HSP may be mistakenly 
diagnosed with cerebral palsy, particularly if there is no family history or history of 
consanguinity that would suggest a genetic etiology.  
Ebrahimi-Fakhari et al.   AP4B1-associated SPG47 
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FIGURE LEGENDS 
FIGURE 1. Facial features of patients with AP4B1-associated SPG47. Shared facial 
characteristics in some individuals include prominent cheeks, a thin upper vermilion 
border and a flat nasal bridge, but features are not characteristic enough to be 
“recognizable”. P1 (2 years, 10 months), P2 (3 years, 8 months), P3 (1 year, 6 months), 
P4 (3 years, 3 months), P5 (3 years, 2 months), P9 (2 years, 11 months). 
FIGURE 2. MRI features of AP4B1-associated SPG47. The top row shows sagittal T1 
weighted images (T2 weighted image in the case of P8) while the bottom row shows 
axial T2 weighted images. The main features consist of a triad that includes 1) a thin 
corpus callosum, particularly affecting the posterior aspect, 2) delayed or decreased 
myelination and 3) ventriculomegaly, often in the form of colpocephaly. 
FIGURE 3. Genetic findings in AP4B1-associated SPG47. Mutations reported in this 
paper are shown above in red; previously reported mutations in black below. 
Parentheses indicate number of unrelated individuals with that mutation. Transcript 
version NM_001253852.1 was used. #: mutation reported here and in previous 
publication 
 
VIDEO 1. Episodes of stereotypic laughter in AP4B1-associated SPG47. This video 
shows a sequence of five patients in whom episodes of stereotypic laughter were 
independently reported.  
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TABLE 2. Core clinical and imaging features of AP4B1-associated SPG47 
Early developmental delay and intellectual disability 100% (19/19) 
Delayed motor development 100% (17/17) 
Neonatal or infantile hypotonia 100% (15/15) 
Delayed speech development 94% (16/17) 
Progression to spastic diplegia 89% (17/19) 
Loss of independent walking 88% (15/17) 
Episodes of stereotypic laughter 77% (10/13) 
Microcephaly (≥ -2SD) 69% (13/19) 
Short stature 57% (8/14) 
Epilepsy 47% (9/19) 
Thin corpus callosum 73% (11/15) 
Delayed myelination or white matter loss 67% (10/15) 
Ventriculomegaly 40% (6/15) 
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TABLE 3. AP4B1 mutation spectrum  
 
Nomenclature based on NM_001253852.1. The EXAC based minor allele frequencies for these variants 
range from zero to 0.00018. Abbreviations: ES (exome sequencing), CADD (Combined Annotation 
Dependent Depletion), Hmz (homozygosity mapping), Panel (multi-gene panel), Sanger (Sanger 
sequencing) See Supplemental Table 1 for complete genomic location, CADD scores, and minor allele 
frequencies. 
  
PATIENT METHOD MUTATION 1 MUTATION 2 
P1  Panel c.1216C>T (p.Arg406*) c.1328T>C (p.Leu443Pro) 
P2  ES 
c.530_531insA 
(p.Asn178Glufs*20) c.114-2A>C 
P3  ES c.1345A>T (p.Arg449*) 
c.1160_1161delCA 
(p.Thr387Argfs*30) 
P4  ES c.1216C>T (p.Arg406*) c.1328T>C (p.Leu443Pro) 
P5  ES c.114-2A>G  c.114-2A>G  
P6  ES c.304C>T (p.Arg102*) c.304C>T (p.Arg102*) 
P7  ES c.304C>T (p.Arg102*) c.304C>T (p.Arg102*) 
P8  ES 
c.664delC 
(p.Leu222Cysfs*31) 
c.664delC 
(p.Leu222Cysfs*31) 
Abdollahpour et al. (P1) ES 
c.1160_1161delCA 
(p.Thr387Argfs*30) 
c.1160_1161delCA 
(p.Thr387Argfs*30) 
Abdollahpour et al. (P2) ES 
c.1160_1161delCA 
(p.Thr387Argfs*30) 
c.1160_1161delCA 
(p.Thr387Argfs*30) 
Tüysüz  et al (P5) Hmz / ES 
c.664delC 
(p.Leu222Cysfs*31) 
c.664delC 
(p.Leu222Cysfs*31) 
Tüysüz  et al. (P6) Hmz / ES 
c.664delC 
(p.Leu222Cysfs*31) 
c.664delC 
(p.Leu222Cysfs*31) 
Lamichane et al. Panel c.313delG (p.Ala105Argfs*52) c.577G>A (p.Val193Ile) 
Abou Jamra et al (IV-2) Hmz / Sanger 
c.487_488insTAT 
(p.Glu163Valfs*2) 
c.487_488insTAT 
(p.Glu163Valfs*2) 
Abou Jamra et al (IV-4) Hmz / Sanger 
c.487_488insTAT 
(p.Glu163Valfs*2) 
c.487_488insTAT 
(p.Glu163Valfs*2) 
Abou Jamra et al (IV-5) Hmz/ Sanger 
c.487_488insTAT 
(p.Glu163Valfs*2) 
c.487_488insTAT 
(p.Glu163Valfs*2) 
Blumkin et al. / Bauer et 
al. (P1) Hmz/ ES 
c.664delC 
(p.Leu222Cysfs*31) 
c.664delC 
(p.Leu222Cysfs*31) 
Blumkin et al. / Bauer et 
al. (P2) Hmz/ ES 
c.664delC 
(p.Leu222Cysfs*31) 
c.664delC 
(p.Leu222Cysfs*31) 
Tan et al. (P1) Panel 
c.311_312delTGinsC 
(p.Leu104Profs*53) c.577G>A (p.Val193Ile) 
Helbig et al. ES c.617G>A (p.Arg206Gln) c.617G>A (p.Arg206Gln) 
Helbig et al. ES 
c.405_409delTGTCA 
(p.Tyr135*) 
c.405_409delTGTCA 
(p.Tyr135*) 
Karaca et al. ES c.955T>C (p.Phe319Leu) c.955T>C (p.Phe319Leu) 
Karaca et al. ES c.1282G>T (p.Glu428*) c.1282G>T (p.Glu428*) 



